Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

NAM5.5

Nicotinamide – Forschung

Hilft vermutlich

7 begutachtete Studien

Was die Evidenz sagt

Hilft vermutlich

Nicotinamide half in etwa der Hälfte (2/3) der Studien, die einen Effekt gemessen haben — vielversprechend, aber nicht einhellig.

Die meiste Evidenz stammt aus hochwertigen randomisierten Studien, veröffentlicht 1995–2026 mit einer typischen Studiengröße von 100 Teilnehmenden.

Basierend auf 7 Studien · 5 RCTs · 898 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Was die Studien gefunden haben

2geholfen1unklar· 4 weitere ohne bewertete Effektdaten

Nach Outcome

Skin cancer & dermatologyReduziert neue Nicht-Melanom-Hautkrebsarten und aktinische Keratosen bei Hochrisiko-Haut; langfristige Anwendung bei Akne · 3-6 Monate (Chemoprävention); 8 Wochen (Akne)
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Kidney & renal health
Zu wenige bewertete Studien2 Studien
NAD+ & healthspan (unproven)Füllt theoretisch NAD+ wieder auf, ein menschlicher Langlebigkeitsnutzen durch NAD+-Vorläufer ist jedoch unbewiesen · Fortlaufend
Zu wenige bewertete Studien1 Studie

In Zahlen

Aus 6 Studien mit messbaren Effekten gezogen

Wahrscheinlich echte Effekte

100%

über Studien hinweg

Untersuchte Personen

898

typische Studie: 100 Personen

Stärkste Designs

0 gepoolt, 5 randomisiert

Zeigte Nutzen

67%

2/3 Studien

Wie lange Studien liefen

3+ Monate

Untersuchte Populationen

High-risk patients with prior non-melanoma skin cancers1

Adults with prior skin cancer1

Chronic hemodialysis patients1

Dermatology / photoaging1

Aktives Forschungsgebiet

3 Studien in den letzten 5 Jahren

199520102026

1New non-melanoma skin cancers at 12 monthsRCTCited 448×n=386 · medium study2015

Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.

Chen AC, Martin AJ, Choy B, et al. · The New England journal of medicine (2015)

Groß Nutzen

← SchlechterKein EffektBesser →

Likely real

ONTRAC: phase-3, double-blind RCT randomizing 386 patients with ≥2 prior non-melanoma skin cancers to 500 mg nicotinamide twice daily or placebo for 12 months
Rate of new non-melanoma skin cancers was 23% lower with nicotinamide than placebo (95% CI 4-38, P=0.02)
Actinic keratoses were 13-20% lower across follow-up time points; no benefit persisted after discontinuation

Quelle ansehen

2Neurocognitive function and quality of lifeRCTn=310 · medium study2019

We were not able to detect any significant effect of oral nicotinamide on cognitive function nor on quality of life.

Martin AJ, Dhillon HM, Vardy JL, et al. · Geriatrics (Basel) (2019)

Kein klarer Effekt

← SchlechterKein EffektBesser →

Pre-specified neurocognitive and quality-of-life sub-study of the ONTRAC RCT (500 mg nicotinamide twice daily vs placebo, 12 months)
In 310 participants completing testing, no significant effect of nicotinamide on cognitive function was detected
No effect on patient-reported quality of life either

Quelle ansehen

3Serum phosphorus lowering (non-inferiority vs sevelamer)RCTn=100 · medium study2017

Both drugs are equally effective in lowering serum phosphorus, but patients' tolerance of NAM was largely inferior to that of SEV.

Lenglet A, Liabeuf S, El Esper N, et al. · Nephrology, dialysis, transplantation (2017)

Multicentre, open-label RCT randomizing 100 chronic hemodialysis patients to nicotinamide or sevelamer for 24 weeks
Nicotinamide and sevelamer lowered serum phosphorus comparably, but non-inferiority was not met (underpowered)
Tolerability was much worse with nicotinamide: only 55% completed vs 90% with sevelamer; thrombocytopenia in four patients

Quelle ansehen

4Nicotinamide mechanism in skin cancer prevention and agingÜbersicht2026

Nicotinamide, the amide form of vitamin B3, has gained increasing attention in dermatology due to its potential role in both skin aging and non-melanoma skin cancer prevention.

Moro F, Panebianco ASI, Bartolocci V, et al. · International journal of molecular sciences (2026)

Review of the biological rationale and clinical evidence for nicotinamide and NAD+ precursors in photoaging and cutaneous carcinogenesis
UV exposure drives DNA damage, oxidative stress, inflammation and immune dysregulation; nicotinamide replenishes NAD+ to support DNA repair and prevent UV-induced ATP depletion
Frames the photoprotective/anti-aging skin mechanism that underlies the ONTRAC chemoprevention result

Quelle ansehen

5Serum phosphate concentrationRCTn=26 · very small study2024

NAM is effective in reducing serum phosphate concentrations in patients with kidney failure receiving hemodialysis... However, more research in larger populations is needed to confirm this.

Schepers L, Jans I, Pot GK, et al. · Journal of renal nutrition (2024)

Spürbar Nutzen

← SchlechterKein EffektBesser →

Randomized crossover trial of niacinamide supplementation on serum phosphate in hemodialysis patients with kidney failure
Niacinamide significantly reduced serum phosphate and was well-tolerated, with no increased thrombocytopenia risk in this study
Positions niacinamide as a possible add-on to combat hyperphosphatemia, contrasting the tolerability problems seen in NICOREN

Quelle ansehen

6NAD+ precursors and healthspanÜbersicht2023

NAD+ levels decrease with age; supplementing NAD+ precursors aims to restore the NAD+ levels present in youth.

Sharma A, Chabloz S, Lapides RA, et al. · Nutrients (2023)

Review of NAD+-promoting compounds — nicotinamide and other precursors (NMN, NR) — as a healthspan strategy
Frames the CD38/NAD+/SIRT1 axis through which NAD+ precursors are proposed to support aging-related pathways
Provides the mechanistic NAD+/longevity rationale for nicotinamide

Quelle ansehen

7RCTn=76 · small study1995

After 8 weeks, both treatments produced comparable (P = 0.19) beneficial results in the Physician's Global Evaluation of Inflammatory Acne; 82% of the patients treated with nicotinamide gel and 68% treated with clindamycin gel were improved.

Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. · Int J Dermatol (1995)

Double-blind RCT: 76 patients with moderate inflammatory acne randomized to 4% nicotinamide gel (n=38) vs 1% clindamycin gel (n=38), twice daily for 8 weeks
Comparable global improvement (82% nicotinamide vs 68% clindamycin, P=0.19) with no significant difference
Supports topical niacinamide as an antibiotic-free acne option of comparable efficacy to clindamycin

Quelle ansehen

In der Forschungsbibliothek ansehen

Nicotinamide – Forschung

Hilft vermutlich

In Zahlen

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.

Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide.

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.

Skin Cancer Prevention and Antiaging: Role of Nicotinamide.

The Effect of Niacinamide Supplementation on Phosphate Concentrations in Dutch Dialysis Patients: A Randomized Crossover Trial.

Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan.

Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris.